688302 海创药业
已收盘 04-28 15:00:01
资讯
新帖
简况
海创药业:治疗MASH药物HP515临床IIa期试验期中分析获积极结果
证券之星 · 04-27 18:29
海创药业:治疗MASH药物HP515临床IIa期试验期中分析获积极结果
4月27日海创药业跌12.16%,鹏华医药科技股票A基金重仓该股
证券之星 · 04-27 16:29
4月27日海创药业跌12.16%,鹏华医药科技股票A基金重仓该股
海创药业(688302)3月31日股东户数0.8万户,较上期减少3.02%
证券之星 · 04-25
海创药业(688302)3月31日股东户数0.8万户,较上期减少3.02%
图解海创药业年报:第四季度单季净利润同比增长16.11%
证券之星 · 04-25
图解海创药业年报:第四季度单季净利润同比增长16.11%
创新药概念午后再度活跃 海创药业涨超11%
每日经济新闻 · 03-31
创新药概念午后再度活跃 海创药业涨超11%
股市必读:海创药业(688302)今年截至3月20日累计跌幅已超20%
证券之星 · 03-23
股市必读:海创药业(688302)今年截至3月20日累计跌幅已超20%
每周股票复盘:海创药业(688302)MASH药物完成IIa期入组
证券之星 · 03-08
每周股票复盘:海创药业(688302)MASH药物完成IIa期入组
海创药业(688302)披露HP515 IIa期临床试验完成全部参与者入组,3月3日股价下跌5.06%
证券之星 · 03-03
海创药业(688302)披露HP515 IIa期临床试验完成全部参与者入组,3月3日股价下跌5.06%
海创药业(688302.SH):治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验完成参与者入组
智通财经 · 03-03
海创药业(688302.SH):治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验完成参与者入组
3月3日海创药业跌5.06%,鹏华医药科技股票A基金重仓该股
证券之星 · 03-03
3月3日海创药业跌5.06%,鹏华医药科技股票A基金重仓该股
股市必读:海创药业发布2025年度业绩快报,亏损1.367亿元
证券之星 · 03-02
股市必读:海创药业发布2025年度业绩快报,亏损1.367亿元
每周股票复盘:海创药业(688302)2025年净亏1.367亿同比减亏
证券之星 · 03-01
每周股票复盘:海创药业(688302)2025年净亏1.367亿同比减亏
马年首周857家公司披露业绩快报,4家净利增速超10倍
21世纪经济报道 · 02-28
马年首周857家公司披露业绩快报,4家净利增速超10倍
海创药业(688302)披露2025年度业绩快报,2月27日股价上涨0.43%
证券之星 · 02-27
海创药业(688302)披露2025年度业绩快报,2月27日股价上涨0.43%
每周股票复盘:海创药业(688302)获GMP认证生产扩容
证券之星 · 02-08
每周股票复盘:海创药业(688302)获GMP认证生产扩容
股市必读:海创药业(688302)预计2025年全年扣除后营业收入:1,900万元至2,200万元
证券之星 · 02-02
股市必读:海创药业(688302)预计2025年全年扣除后营业收入:1,900万元至2,200万元
每周股票复盘:海创药业(688302)募投项目延期至2026年底
证券之星 · 2025-12-28
每周股票复盘:海创药业(688302)募投项目延期至2026年底
储能行业点评报告:全球首款锂钠协同储能方案发布,AIDC配储增量可期
华龙证券 · 2025-12-22
储能行业点评报告:全球首款锂钠协同储能方案发布,AIDC配储增量可期
12月11日海创药业涨6.32%,鹏华医药科技股票A基金重仓该股
证券之星 · 2025-12-11
12月11日海创药业涨6.32%,鹏华医药科技股票A基金重仓该股
创新药概念局部活跃 海创药业涨超11%
每日经济新闻 · 2025-12-11
创新药概念局部活跃 海创药业涨超11%
加载更多
公司概况
公司名称:
海创药业股份有限公司
所属行业:
医药制造业
上市日期:
2022-04-12
主营业务:
海创药业股份有限公司的主营业务是药品的研发、生产、销售以及技术咨询、技术转让。公司的主要产品是氘恩扎鲁胺软胶囊。公司高度重视科研实力的积累,经过多年发展,逐渐积累了一批创新药研发领域富有经验、创新精神和全球视野的专家技术团队,其中包括有2位国家级人才和多位四川省级人才,领导或参与了国内外多个创新药的研发、上市及产业化。公司不断完善创新药研发团队,提高团队的科研能力。报告期内,公司承担四川省科技厅1项重大科技专项、1项重点研发项目。
发行价格:
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":40.96,"timestamp":1777359601000,"preClose":41.03,"halted":0,"volume":1645967,"delay":0,"changeRate":-0.0017,"floatShares":99015600,"shares":99015600,"eps":-1.3638,"marketStatus":"已收盘","change":-0.07,"latestTime":"04-28 15:00:01","open":41.8,"high":42.73,"low":40.2,"amount":68241400,"amplitude":0.0617,"askPrice":40.99,"askSize":97,"bidPrice":40.96,"bidSize":9,"shortable":0,"etf":0,"ttmEps":-1.3638,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777426200000},"marketStatusCode":5,"adr":0,"adjPreClose":41.03,"symbolType":"stock_kcb","openAndCloseTimeList":[[1777339800000,1777347000000],[1777352400000,1777359600000]],"highLimit":45.13,"lowLimit":36.93,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":99015598,"isCdr":false,"pbRate":3.92,"roa":"--","roe":"--","epsLYR":-1.39,"committee":-0.104839,"marketValue":4056000000,"turnoverRate":0.0166,"status":1,"afterMarket":{"amount":0,"volume":0,"close":40.96,"buyVolume":0,"sellVolume":0,"time":1777361637558,"indexStatus":"已收盘 04-28 15:30:00","preClose":41.03},"floatMarketCap":4056000000},"requestUrl":"/m/hq/s/688302","defaultTab":"news","newsList":[{"id":"2630608033","title":"海创药业:治疗MASH药物HP515临床IIa期试验期中分析获积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2630608033","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630608033?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:29","pubTimestamp":1777285782,"startTime":"0","endTime":"0","summary":"海创药业公告称,公司自主研发的治疗代谢相关脂肪性肝炎药物HP515临床IIa期试验取得期中分析积极结果。安全性方面,各剂量组总体耐受性良好,未报告严重不良事件、重度不良事件或与药物相关的退出,绝大多数不良事件为轻中度且呈一过性。截至公告日,国内无同类靶点产品获批上市。该结果对公司近期经营业绩无重大影响,投资者需注意研发及市场风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700034581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336631","title":"4月27日海创药业跌12.16%,鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336631","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630336631?lang=zh_cn&edition=full","pubTime":"2026-04-27 16:29","pubTimestamp":1777278550,"startTime":"0","endTime":"0","summary":"证券之星消息,4月27日海创药业跌12.16%,收盘报41.03元,换手率3.15%,成交量3.12万手,成交额1.32亿元。重仓海创药业的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为16.53亿元,最新净值1.6872,较上一交易日下跌0.5%,近一年上涨24.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700029243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1515","159938","09939","BK1161","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630870303","title":"海创药业(688302)3月31日股东户数0.8万户,较上期减少3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870303","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870303?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:06","pubTimestamp":1777108009,"startTime":"0","endTime":"0","summary":"证券之星消息,近日海创药业披露,截至2026年3月31日公司股东户数为7984.0户,较12月31日减少249.0户,减幅为3.02%。在化学制药行业个股中,海创药业股东户数低于行业平均水平,截至3月31日,化学制药行业平均股东户数为3.52万户。从股价来看,2025年12月31日至2026年3月31日,海创药业区间跌幅为10.47%,在此期间股东户数减少249.0户,减幅为3.02%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500032218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630829710","title":"图解海创药业年报:第四季度单季净利润同比增长16.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630829710","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630829710?lang=zh_cn&edition=full","pubTime":"2026-04-25 01:26","pubTimestamp":1777051575,"startTime":"0","endTime":"0","summary":"证券之星消息,海创药业2025年年报显示,当年度公司主营收入2046.99万元,同比上升5480.11%;归母净利润-1.37亿元,同比上升31.2%;扣非净利润-1.68亿元,同比上升22.82%;其中2025年第四季度,公司单季度主营收入-288.19万元,同比下降1220.93%;单季度归母净利润-3810.54万元,同比上升16.11%;单季度扣非净利润-4796.7万元,同比上升4.39%;负债率18.8%,投资收益518.41万元,财务费用-634.89万元,毛利率98.62%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500004149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623308309","title":"创新药概念午后再度活跃 海创药业涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623308309","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623308309?lang=zh_cn&edition=full","pubTime":"2026-03-31 13:50","pubTimestamp":1774936200,"startTime":"0","endTime":"0","summary":"每经AI快讯,3月31日,创新药概念午后再度活跃,海创药业涨超11%,此前津药药业、凯莱英涨停,双鹭药业、首药控股、亚太药业、威尔药业、万邦德、诚达药业跟涨。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690242481.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690242481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06978","BK1574","688302","BK1161","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621749873","title":"股市必读:海创药业(688302)今年截至3月20日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621749873","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621749873?lang=zh_cn&edition=full","pubTime":"2026-03-23 03:47","pubTimestamp":1774208829,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘,海创药业报收于38.84元,下跌4.22%,换手率1.07%,成交量1.06万手,成交额4215.71万元。交易信息汇总股价提醒3月20日海创药业收盘报38.84元,跌4.22%,当日成交106.19万元。根据收盘数据统计,该股已连续2日下跌,当年累计跌幅21.02%。前10个交易日资金流向情况:主力资金累计净流出1524.7万元,股价累计下跌8.83%;融资余额累计增加571.52万元,融券余量累计增加0股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300001489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617800663","title":"每周股票复盘:海创药业(688302)MASH药物完成IIa期入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2617800663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617800663?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:57","pubTimestamp":1772909828,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,海创药业报收于42.6元,较上周的44.19元下跌3.6%。本周,海创药业3月2日盘中最高价报44.1元。本周关注点公司公告汇总:HP515片治疗MASH的IIa期临床试验完成全部参与者入组。HP515为口服高选择性THR-β激动剂,已获中国和美国药品监管部门批准开展MASH适应症临床试验。截至目前,国内尚无同类靶点产品获批上市。该进展对公司近期业绩无重大影响,后续存在研发不确定性风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616299423","title":"海创药业(688302)披露HP515 IIa期临床试验完成全部参与者入组,3月3日股价下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616299423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616299423?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:36","pubTimestamp":1772548580,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘,海创药业报收于40.15元,较前一交易日下跌5.06%,最新总市值为39.75亿元。该股当日开盘42.47元,最高42.88元,最低40.0元,成交额达8007.17万元,换手率为1.97%。近日,海创药业股份有限公司自愿披露,其自主研发的治疗代谢相关脂肪性肝炎药物HP515的IIa期临床试验已顺利完成全部参与者入组。HP515为口服THR-β激动剂,前期I期试验显示其在安全性、药代动力学及药效学方面表现良好,SHBG呈剂量依赖性上升,血脂指标LDL-C、TC、ApoB显著下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300044567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616344597","title":"海创药业(688302.SH):治疗代谢相关脂肪性肝炎(MASH)药物HP515临床IIa期试验完成参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344597","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616344597?lang=zh_cn&edition=full","pubTime":"2026-03-03 19:42","pubTimestamp":1772538125,"startTime":"0","endTime":"0","summary":"智通财经APP讯,海创药业(688302.SH)公告,公司自主研发的拟用于治疗代谢相关脂肪性肝炎(MASH,曾用名非酒精性脂肪性肝炎(NASH))的HP515临床IIa期试验于近日已完成全部参与者入组。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616317863","title":"3月3日海创药业跌5.06%,鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616317863","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616317863?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:36","pubTimestamp":1772527004,"startTime":"0","endTime":"0","summary":"证券之星消息,3月3日海创药业跌5.06%创60日新低,收盘报40.15元,换手率1.97%,成交量1.95万手,成交额8007.17万元。重仓海创药业的公募基金请见下表:根据2025基金年报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为17.21亿元,最新净值1.6766,较上一交易日下跌1.9%,近一年上涨43.4%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300029022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159938","BK0239","688302","BK1515","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616140876","title":"股市必读:海创药业发布2025年度业绩快报,亏损1.367亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616140876","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616140876?lang=zh_cn&edition=full","pubTime":"2026-03-02 03:10","pubTimestamp":1772392224,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,海创药业报收于44.19元,上涨0.43%,换手率0.7%,成交量6971.0手,成交额3061.84万元。业绩披露要点业绩快报海创药业近日即将发布2025年年报,根据2月27日发布的业绩快报,归属净利润亏损1.367亿元,同比增长31.48%。业绩增长主要因首个1类新药氘恩扎鲁胺软胶囊于2025年5月获批上市并实现销售收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616456138","title":"每周股票复盘:海创药业(688302)2025年净亏1.367亿同比减亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2616456138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616456138?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:45","pubTimestamp":1772304313,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,海创药业报收于44.19元,较上周的45.1元下跌2.02%。本周,海创药业2月24日盘中最高价报45.63元。本周关注点来自业绩披露要点:海创药业2025年归属净利润亏损1.367亿元,同比减亏31.48%。公司公告汇总海创药业发布2025年度业绩快报,营业总收入2,067.38万元,同比增长5,535.71%;归属于母公司所有者的净利润为-13,668.75万元,同比减亏6,280.83万元。业绩增长主要因首个1类新药氘恩扎鲁胺软胶囊于2025年5月获批上市并实现销售收入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614468811","title":"马年首周857家公司披露业绩快报,4家净利增速超10倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2614468811","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614468811?lang=zh_cn&edition=full","pubTime":"2026-02-28 20:15","pubTimestamp":1772280900,"startTime":"0","endTime":"0","summary":" 马年首周,A股上市公司业绩迎来密集披露。 21快讯记者据同花顺iFind统计,截至2月28日,马年首周已有857家A股上市公司披露2025年业绩快报,470家归母净利润实现同比增长,其中电子、机械设备和医药生物行业占比位居前三,分别为97家、77家和69家,具备较强的业绩基本面支撑。业绩快报显示,海创药业2025年实现营业收入0.21亿元,同比激增5536.26%。然而,2025年公司归母净利润仍亏损1.37亿元,不过较去年同期已减亏31.48%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-28/doc-inhpkpem2997655.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-28/doc-inhpkpem2997655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SINA","SGXZ49509284.SGD","BK0224","BK0214","688302","BK0239","688498","688223","SGXZ81163826.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614857037","title":"海创药业(688302)披露2025年度业绩快报,2月27日股价上涨0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857037","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614857037?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:17","pubTimestamp":1772205430,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,海创药业报收于44.19元,较前一交易日上涨0.43%,最新总市值为43.75亿元。该股当日开盘43.53元,最高44.25元,最低43.49元,成交额达3061.84万元,换手率为0.7%。近日,海创药业披露2025年度业绩快报。业绩变动主要因首个1类新药氘恩扎鲁胺软胶囊于2025年5月获批上市并实现销售收入。截至2025年末,公司总资产为131,470.03万元,同比减少3.44%;归属于母公司的所有者权益为106,412.38万元,同比减少10.75%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609185526","title":"每周股票复盘:海创药业(688302)获GMP认证生产扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2609185526","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609185526?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:00","pubTimestamp":1770490837,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,海创药业报收于45.83元,较上周的46.0元下跌0.37%。本周,海创药业2月6日盘中最高价报46.67元。本周关注点公司公告汇总:海创药业软胶囊剂生产线通过GMP符合性检查,生产范围新增抗肿瘤药。此次变更有助于公司优化生产结构,提升核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608092881","title":"股市必读:海创药业(688302)预计2025年全年扣除后营业收入:1,900万元至2,200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608092881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608092881?lang=zh_cn&edition=full","pubTime":"2026-02-02 05:06","pubTimestamp":1769979978,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,海创药业报收于46.0元,下跌0.28%,换手率1.24%,成交量1.23万手,成交额5671.17万元。业绩披露要点业绩预告海创药业发布业绩预告,预计2025年全年归属净利润亏损1.25亿元至1.5亿元;扣非后净利润亏损1.55亿元至1.85亿元;营业收入预计为1900万元至2200万元;扣除后营业收入为1900万元至2200万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2594424402","title":"每周股票复盘:海创药业(688302)募投项目延期至2026年底","url":"https://stock-news.laohu8.com/highlight/detail?id=2594424402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594424402?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:17","pubTimestamp":1766866628,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,海创药业报收于50.29元,较上周的52.44元下跌4.1%。本周,海创药业12月22日盘中最高价报53.15元。会议审议通过《关于审议豁免本次会议通知时限的议案》和《关于首次公开发行股票部分募投项目延期的议案》。董事会认为项目延期系基于实际情况的审慎决定,程序合规,未损害股东利益。“研发生产基地建设项目”原定于2025年12月31日达到预定可使用状态,现调整至2026年12月31日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593482191","title":"储能行业点评报告:全球首款锂钠协同储能方案发布,AIDC配储增量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2593482191","media":"华龙证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593482191?lang=zh_cn&edition=full","pubTime":"2025-12-22 20:07","pubTimestamp":1766405252,"startTime":"0","endTime":"0","summary":"全球首款锂钠协同储能方案发布。AIDC配储渗透率及配储时长有望提升,我们测算2030年AIDC配储需求或超100gwh。我们认为2026年储能市场或延续高速增长态势,AIDC配套储能系统有望迎来规模化部署高峰期,大储市场需求正向“4小时及更长时长”迁移。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222200743a6c167ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222200743a6c167ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688472","LU1152091168.USD","LU1993786604.SGD","LU0880133367.SGD","002150","688302","LU1152091754.HKD","300750","LU1807302812.USD","LU1960683339.HKD","300014","03750","BK1610","688599","300274","BK1116","LU0067412154.USD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2590560774","title":"12月11日海创药业涨6.32%,鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590560774","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590560774?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:33","pubTimestamp":1765438438,"startTime":"0","endTime":"0","summary":"证券之星消息,12月11日海创药业涨6.32%创60日新高,收盘报57.0元,换手率7.01%,成交量6.94万手,成交额3.96亿元。该股为创新药、医药概念热股。重仓海创药业的公募基金请见下表:根据2025基金Q3季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为19.21亿元,最新净值1.7336,较上一交易日上涨0.14%,近一年上涨57.61%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","09939","BK1515","BK1574","688302","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590566181","title":"创新药概念局部活跃 海创药业涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590566181","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590566181?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:09","pubTimestamp":1765422540,"startTime":"0","endTime":"0","summary":"每经AI快讯,12月11日,创新药概念局部活跃,海创药业涨超11%,前沿生物涨超8%,重药控股此前涨停,悦康药业、热景生物、回盛生物、众生药业跟涨。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhakwan8087335.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhakwan8087335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1574","688302","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777422381668,"stockEarnings":[{"period":"1week","weight":-0.0752},{"period":"1month","weight":0.0064},{"period":"3month","weight":-0.1328},{"period":"6month","weight":-0.2355},{"period":"1year","weight":0.0549},{"period":"ytd","weight":-0.167}],"compareEarnings":[{"period":"1week","weight":-0.0016},{"period":"1month","weight":0.0421},{"period":"3month","weight":-0.0175},{"period":"6month","weight":0.023},{"period":"1year","weight":0.2403},{"period":"ytd","weight":0.0277}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海创药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"7984人(较上一季度减少3.02%)","perCapita":"12401股","listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","registeredCapital":"9901万元","survey":" 海创药业股份有限公司的主营业务是药品的研发、生产、销售以及技术咨询、技术转让。公司的主要产品是氘恩扎鲁胺软胶囊。公司高度重视科研实力的积累,经过多年发展,逐渐积累了一批创新药研发领域富有经验、创新精神和全球视野的专家技术团队,其中包括有2位国家级人才和多位四川省级人才,领导或参与了国内外多个创新药的研发、上市及产业化。公司不断完善创新药研发团队,提高团队的科研能力。报告期内,公司承担四川省科技厅1项重大科技专项、1项重点研发项目。","listedPrice":42.92},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}